Wells Fargo lowered the firm’s price target on Calumet (CLMT) to $21 from $23 and keeps an Overweight rating on the shares. The firm says the Path to MaxSAF remains on schedule, but more importantly, significantly cheaper. Potential dispositions provide a bridge for any debt reduction, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Coinbase, Caterpillar upgraded: Wall Street’s top analyst calls
- Calumet initiated with a Buy at BofA
- Positive Outlook for Calumet Specialty Products Driven by Operational Performance and Strategic Financial Maneuvers
- Calumet Specialty Products: Hold Rating Amid Rising Net Debt and Uncertain Earnings Outlook
- Calumet Specialty Products Reports Q1 2025 Results